Lucira Health to Announce Second Quarter 2022 Financial Results
Rhea-AI Summary
Lucira Health, a medical technology company specializing in innovative infectious disease test kits, will report its second quarter 2022 financial results on August 15, 2022. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide updates. Lucira's testing platform includes consumer-friendly kits designed for reliable, on-the-spot molecular test results within 30 minutes, significantly enhancing accessibility to COVID-19 testing. For more details, visit their website.
Positive
- Innovative testing platform providing lab-quality molecular testing.
- Rapid results for COVID-19 testing within 30 minutes.
Negative
- None.
News Market Reaction – LHDX
In the trading session that priced this news, LHDX declined 3.72%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A replay of the webcast can be accessed via the Events page of the investor section of Lucira's website.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease kits. Lucira’s testing platform produces lab-quality molecular testing in a single-use, consumer friendly, palm-size test kit powered by two AA batteries. Lucira designed its test kit to provide accurate, reliable, and on-the-spot molecular test results anywhere and at any time. The Lucira™ Check-It COVID-19 Test Kit (OTC) and Lucira™ COVID-19 All-In-One Test Kit (Rx) are designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. For more information, visit www.lucirahealth.com
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230
